ADC Therapeutics SA (NYSE:ADCT)
$ 2.93 -0.05 (-1.68%) Market Cap: 283.30 Mil Enterprise Value: 112.41 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

Q3 2020 ADC Therapeutics SA Earnings Call Transcript

Nov 12, 2020 / 01:30PM GMT
Release Date Price: $33.96 (-2.05%)
Operator

Thank you for holding. Good morning, and welcome to ADC Therapeutics Third Quarter 2020 Financial and Operating Results Call.

(Operator Instructions) Please be advised that this call is being recorded at the company's request.

At this time, I'd like to turn it over to Amanda Hamilton, Investor Relations Manager at ADC Therapeutics. Please proceed.

Amanda Hamilton
ADC Therapeutics SA - IR Officer

Thank you, operator. This morning, we issued a press release announcing our third quarter 2020 financial results and business updates. This release is available on the ADCT website at ir.adctherapeutics.com under the Press Releases section.

On today's call, Chris Martin, Chief Executive Officer; Jay Feingold, Chief Medical Officer; and Jen Creel, Chief Financial Officer, will discuss recent business highlights and review our third quarter 2020 financial results. In addition, Jennifer Herron, our Chief Commercial Officer, will be available for questions.

As a reminder, this conference call may contain statements that constitute

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot